Echo IQ shares sink 42% as FDA upholds rejection
Echo IQ (ASX:EIQ) shares fell 42.11% after the US Food and Drug Administration (FDA) upheld its decision not to clear the company’s EchoSolv HF heart failure AI tool, following a review of Echo IQ’s appeal.










